Probe Questions Arcosa’s $150 Per Share Sale to CRH Over Fairness
ACA•Arcosa is facing a shareholder investigation into its $150 per share sale to CRH, with claims insiders may gain disproportionate benefits and deal terms could block superior bids. Shareholders are being urged to explore legal options under a contingent-fee arrangement at no out-of-pocket cost.
1. Arcosa Acquisition Details
Arcosa agreed to a $150 per share acquisition by CRH, representing a premium over its recent trading range. The transaction is subject to customary regulatory approvals and contains provisions that could limit competing bids.
2. Investigation Allegations
A shareholder rights firm alleges potential breaches of fiduciary duty, claiming insiders may receive benefits not afforded to ordinary shareholders. The investigation also asserts the deal’s terms could block superior offers.
3. Shareholder Options
Shareholders are encouraged to contact the firm at no cost and may seek increased consideration, additional disclosures or other relief. Representation is offered on a contingent-fee basis, with no up-front legal fees.
